02 April 2020
EMA/CHMP/114813/2020
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for medicinal products for human use (CHMP)

Minutes of the meeting on 27-30 January 2020

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, the minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction 7
1.1. Welcome and declarations of interest of members, alternates and experts 7
1.2. Adoption of agenda 7
1.3. Adoption of the minutes 7

2. Oral Explanations 8
2.1. Pre-authorisation procedure oral explanations 8
2.1.1. selinexor - Orphan - EMEA/H/C/005127 8
2.1.2. Vaxchora - cholera vaccine, oral, live - EMEA/H/C/003876 8
2.2. Re-examination procedure oral explanations 8
2.3. Post-authorisation procedure oral explanations 8
2.3.1. Emgality - galcanezumab - EMEA/H/C/004648/X/0004 8
2.3.2. WS1372 OPDIVO - nivolumab - EMEA/H/C/003985/WS1372/0053 Yervoy - ipilimumab - EMEA/H/C/002213/WS1372/0057 9
2.4. Referral procedure oral explanations 9

3. Initial applications 9
3.1. Initial applications; Opinions 9
3.1.1. Arsenic trioxide Mylan - arsenic trioxide - EMEA/H/C/005235 9
3.1.2. Azacitidine betapharm - azacitidine - EMEA/H/C/005075 10
3.1.3. Azacitidine Mylan - azacitidine - EMEA/H/C/004984 10
3.1.4. Budesonide/Formoterol Teva Pharma B.V. - budesonide / formoterol fumarate dihydrate - EMEA/H/C/004882 11
3.1.5. Cinacalcet Accordpharma - cinacalcet - EMEA/H/C/005236 11
3.1.6. Givlaari - givosiran - Orphan - EMEA/H/C/004775 12
3.1.7. Liumjev - insulin lispro - EMEA/H/C/005037 12
3.1.8. Nilemdo - bempedoic acid - EMEA/H/C/004958 13
3.1.9. Nustendi - bempedoic acid / ezetimibe - EMEA/H/C/004959 13
3.1.10. Nubeqa - darolutamide - EMEA/H/C/004790 14
3.1.11. Ruxience - rituximab - EMEA/H/C/004696 14
3.1.12. Rybelsus - semaglutide - EMEA/H/C/004953 15
3.1.13. Staquis - crisaborole - EMEA/H/C/004863 15
3.1.14. Trepulmix - treprostinil sodium - Orphan - EMEA/H/C/005207 16
3.1.15. Vaxchora - cholera vaccine, oral, live - EMEA/H/C/003876 16
3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) 17
3.2.1. indacaterol / mometasone furoate - EMEA/H/C/005067 17
3.2.2. budesonide / glycopyrronium / formoterol fumarate dihydrate - EMEA/H/C/004983 17
3.2.3. indacaterol / glycopyrronium / mometasone - EMEA/H/C/005061 17
3.2.4. pretomanid - Orphan - EMEA/H/C/005167 18
3.2.5. selinexor - Orphan - EMEA/H/C/005127 18
3.2.6. indacaterol / glycopyrronium / mometasone - EMEA/H/C/005518 18
3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) 19
3.3.1. abiraterone acetate - EMEA/H/C/005408 19
3.3.2. bevacizumab - EMEA/H/C/005181 19

3.3.3. bulevirtide - Orphan - EMEA/H/C/004854 19
3.3.4. elexacaftor / tezacaftor / ivacaftor - Orphan - EMEA/H/C/005269 19
3.3.5. lenalidomide - EMEA/H/C/005306 20
3.3.6. pegfilgrastim - EMEA/H/C/005085 20
3.3.7. somapacitan - Orphan - EMEA/H/C/005030 20
3.4. Update on on-going initial applications for Centralised procedure 20
3.4.1. abicipar pegol - EMEA/H/C/005103 20
3.4.2. ioflupane (^{123}I) - EMEA/H/C/005135 21
3.4.3. satralizumab - Orphan - EMEA/H/C/004788 21
3.4.4. rilpivirine - EMEA/H/C/005060 21
3.4.5. entrectinib - EMEA/H/C/004936 21
3.4.6. pexidartinib - Orphan - EMEA/H/C/004832 22
3.4.7. cabotegravir - EMEA/H/C/004976 22
3.4.8. ozanimod - EMEA/H/C/004835 22
3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 23
3.5.1. Hopveus - sodium oxybate - EMEA/H/C/004962 23
3.6. Initial applications in the decision-making phase 23
3.7. Withdrawals of initial marketing authorisation application 23

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 23

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion 23
4.1.1. Halimatoz - adalimumab - EMEA/H/C/004866/X/0013 23
4.1.2. Hefiya - adalimumab - EMEA/H/C/004865/X/0013 24
4.1.3. Hyrimoz - adalimumab - EMEA/H/C/004320/X/0013 24
4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues 25
4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question 25
4.3.1. IDELVION - albutrepenonacog alfa - Orphan - EMEA/H/C/003955/X/0035 25
4.3.2. Pemetrexed Accord - pemetrexed - EMEA/H/C/004072/X/0010 25
4.3.3. Velphoro - iron - EMEA/H/C/002705/X/0020/G 25
4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 26
4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 26

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 26

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information 26
5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0070 26
5.1.2. Ameluz - 5-aminolevulinic acid - EMEA/H/C/002204/II/0039/G 27
5.1.3. CRYSVITA - burosumab - Orphan - EMEA/H/C/004275/II/0010/G 27
5.1.4. ECALTA - anidulafungin - EMEA/H/C/000788/II/0040 28
5.1.5. INTELENCE - etravirine - EMEA/H/C/000900/II/0058 28
5.1.6. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0082 29

5.1.7. Kineret - anakinra - EMEA/H/C/000363/II/0070 29
5.1.8. Lynparza - olaparib - EMEA/H/C/003726/II/0033 29
5.1.9. MabThera - rituximab - EMEA/H/C/000165/II/0162 30
5.1.10. MabThera - rituximab - EMEA/H/C/000165/II/0168 30
5.1.11. Rezolsta - darunavir / cobicistat - EMEA/H/C/002819/II/0033 31
5.1.12. Ruconest - conestat alfa - EMEA/H/C/001223/II/0053/G 32
5.1.13. Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/II/0011 32
5.1.14. Taltz - ixekizumab - EMEA/H/C/003943/II/0031 33
5.1.15. Tremfya - guselkumab - EMEA/H/C/004271/II/0017 33
5.1.16. Tybost - cobicistat - EMEA/H/C/002572/II/0051 34
5.1.17. Venclyxto - venetoclax - EMEA/H/C/004106/II/0023/G 34
5.1.18. WS1695 Braftovi - encorafenib - EMEA/H/C/004580/WS1695/0008 Mektovi - binimetinib - EMEA/H/C/004579/WS1695/0007 35
5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 35
5.2.1. Brilique - ticagrelor - EMEA/H/C/001241/II/0047/G 35
5.2.2. Fycompa - perampanel - EMEA/H/C/002434/II/0047 36
5.2.3. OFEV - nintedanib - Orphan - EMEA/H/C/003821/II/0026 36
5.2.4. OFEV - nintedanib - Orphan - EMEA/H/C/003821/II/0027 37
5.2.5. Axumin - fluciclovine (^{18}F) - EMEA/H/C/004197/II/0011 37
5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 37

6. Ancillary medicinal substances in medical devices 38
6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions 38
6.2. Update of Ancillary medicinal substances in medical devices 38

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 38
7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 38

8. Pre-submission issues 38
8.1. Pre-submission issue 38
8.1.1. crisantaspase - H0005424 38
8.1.2. Combination of bifikafusp alfa and onfekafusp alfa - H0005385 and H0005370 38
8.1.3. dostarlimab - H0005204 39
8.2. Priority Medicines (PRIME) 39
8.2.1. List of applications received 39
8.2.2. Recommendation for PRIME eligibility 39

9. Post-authorisation issues 39
9.1. Post-authorisation issues 39
9.1.1. ECALTA - anidulafungin - EMEA/H/C/000788 39
9.1.2. Fexeric (EXP) - ferric citrate coordination complex - EMEA/H/C/003776 40
9.1.3. Olanzapine Apotex - olanzapine - EMEA/H/C/001178/II/0037 40
9.1.4. Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/II/0049 40
9.1.5. Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0049 40
9.1.6. Stelara - ustekinumab - EMEA/H/C/000958/II/0073 41

9.1.7. Varuby - rolapitant - EMEA/H/C/004196 41
9.1.8. WS1587/G Abasaglar-EMEA/H/C/002835/WS1587/0028/G Humalog-EMEA/H/C/000088/WS1587/0178/G 41
9.1.9. Yondelis - trabectedin- EMEA/H/C/000773 42
9.1.10. Zynteglo - autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin BB305 lentiviral vector encoding the beta-A-T87Q-globin gene - EMEA/H/C/003691/R/0005, Orphan, ATMP 42

10. Referral procedures 43

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004 43
10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 43
10.2.1. Direct Oral Anticoagulants (DOAC) - EMEA/H/A-5(3)/1478 43
10.2.2. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490 43
10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 44
10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC 44
10.4.1. Budesonide SUN – budesonide – EMEA/H/A-29(4)/1492 44
10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC 44
10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC 45
10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC 45
10.8. Procedure under Article 107(2) of Directive 2001/83/EC 45
10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 45
10.10. Procedure under Article 29 of Regulation (EC) 1901/2006 45
10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 45

11. Pharmacovigilance issue 45

11.1. Early Notification System 45

12. Inspections 45

12.1. GMP inspections 45
12.2. GCP inspections 46
12.3. Pharmacovigilance inspections 46
12.4. GLP inspections 46

13. Innovation Task Force 46

13.1. Minutes of Innovation Task Force 46
13.2. Innovation Task Force briefing meetings 46
13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 46
13.4. Nanomedicines activities 46

14. Organisational, regulatory and methodological matters 46

14.1. Mandate and organisation of the CHMP 46
14.2. Coordination with EMA Scientific Committees 46
14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) 46
14.2.2. Committee for Advanced Therapies (CAT) 47

14.2.3. Committee for Herbal Medicinal Products (HMPC) 47
14.2.4. Committee for Orphan Medicinal Products (COMP) 47
14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 47
14.3.1. Biologics Working Party (BWP) 47
14.3.2. Central Nervous System Working Party (CNSWP) 48
14.3.3. Name Review Group (NRG) 48
14.3.4. Scientific Advice Working Party (SAWP) 48
14.3.5. Safety Working Party (SWP) 48
14.3.6. Quality Working Party (QWP) 48
14.4. Cooperation within the EU regulatory network 48
14.5. Cooperation with International Regulators 48
14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee 49
14.7. CHMP work plan 49
14.7.1. CHMP 2020 Work Plan 49
14.8. Planning and reporting 49
14.9. Others 49

15. Any other business 49

15.1. AOB topic 49
15.1.1. Presentation on Corona Viruses 49
15.1.2. Oncology Training 49

16. List of participants 50

17. Explanatory notes 55

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See (current) January 2020 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 27-30 January 2020 (to be published post February 2020 CHMP meeting).

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 27-30 January 2020

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 09-12 December 2019

The CHMP adopted the minutes.

ORGAM Minutes 20 January 2020

The Minutes of the January 2020 CHMP ORGAM meeting held on 20 January 2020, together with all decisions taken at that meeting, were adopted.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. selinexor - Orphan - EMEA/H/C/005127

Karyopharm Europe GmbH; treatment of patients with relapsed refractory multiple myeloma (RRMM)

Scope: Possible Oral explanation/List of Outstanding Issues

Action: Oral explanation to be held on Tuesday, 28 January 2020 at 11:00

List of Outstanding Issues adopted on 19.09.2019. List of Questions adopted on 24.04.2019.

The CHMP agreed that no oral explanation is needed this time.

See 3.2

2.1.2. Vaxchora - cholera vaccine, oral, live - EMEA/H/C/003876

Emergent Netherlands B.V.; indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 6 years and older

Scope: Possible Oral explanation/Opinion

Action: Oral explanation to be held on Tuesday, 28 January 2020 at 14:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 17.10.2019. List of Questions adopted on 29.05.2019.

The CHMP agreed that no oral explanation is needed this time.

See 3.1

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Emgality - galcanezumab - EMEA/H/C/004648/X/0004

Eli Lilly Nederland B.V.

Rapporteur: Daniela Melchiorri (IT) (MNAT with ES for Quality), Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension application to add a new strength of 100 mg/ml solution for injection in pre-filled syringe for Emgality, associated with a new indication (episodic cluster

headache)."

Draft list of experts for SAG Neurology meeting held on 20 January 2020 adopted via written procedure on 17 January 2020, SAG Report

Oral explanation

Action: Oral explanation to be held on Wednesday, 29 January 2020 at 09:00

List of Outstanding Issues adopted on 17.10.2019. List of Questions adopted on 27.06.2019.

An oral explanation was held on Wednesday, 29 January 2020.

2.3.2. WS1372
OPDIVO - nivolumab - EMEA/H/C/003985/WS1372/0053
Yervoy - ipilimumab - EMEA/H/C/002213/WS1372/0057

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Jorge Camarero Jiménez, Lead Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include first-line treatment of adult patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC) for OPDIVO and Yervoy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add information from the pivotal study CA209227 (an open-label, randomised phase 3 trial of nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in subjects with chemotherapy-naïve stage IV or recurrent NSCLC). The Package Leaflet and RMP (version 14.0 for Opdivo and version 21.0 for Yervoy) are updated in accordance. In addition, the MAH has taken the opportunity to introduce minor editorial and formatting revisions in the PI."

Oral explanation

Action: Oral explanation to be held on Tuesday, 28 January 2020 at 16:00

Request for Supplementary Information adopted on 14.11.2019, 13.12.2018, 26.07.2018.

An oral explanation was held on Tuesday, 28 January 2020.

The CHMP noted that the applicant withdrew the application.

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Arsenic trioxide Mylan - arsenic trioxide - EMEA/H/C/005235

Mylan Ireland Limited; treatment of relapsed acute promyelocytic leukaemia (APL)

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TRISENOX

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 25.07.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 29.01.2020.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.2. Azacitidine betapharm - azacitidine - EMEA/H/C/005075

betapharm Arzneimittel GmbH; Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Vidaza

List of Outstanding Issues adopted on 12.12.2019, 17.10.2019. List of Questions adopted on 29.05.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 31.01.2020.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.3. Azacitidine Mylan - azacitidine - EMEA/H/C/004984

Mylan Ireland Limited; Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Vidaza

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 25.07.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.4. Budesonide/Formoterol Teva Pharma B.V. - budesonide / formoterol fumarate dihydrate - EMEA/H/C/004882

Teva Pharma B.V.; treatment of asthma and COPD

Scope: Opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Questions adopted on 17.10.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.5. Cinacalcet Accordpharma - cinacalcet - EMEA/H/C/005236

Accord Healthcare S.L.U.; treatment of secondary hyperparathyroidism and hypercalcaemia

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Mimpara

List of Outstanding Issues adopted on 12.12.2019, 17.10.2019. List of Questions adopted on 29.05.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 16.12.2019.

The summary of opinion was circulated for information.

3.1.6. Givlaari - givosiran - Orphan - EMEA/H/C/004775

Alnylam Netherlands B.V.; Treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 10.12.2019. List of Questions adopted on 15.10.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that givosiran is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 30.01.2020.

The summary of opinion was circulated for information.

3.1.7. Liumjev - insulin lispro - EMEA/H/C/005037

Eli Lilly Nederland B.V.; Treatment of diabetes mellitus in adults

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.11.2019. List of Questions adopted on 25.07.2019.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 27.01.2020.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.8. Nilemdo - bempedoic acid - EMEA/H/C/004958

FGK Representative Service GmbH; treatment of primary hypercholesterolaemia or mixed dyslipidaemia

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.11.2019. List of Questions adopted on 27.06.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that bempedoic acid is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 30.01.2020.

The summary of opinion was circulated for information.

3.1.9. Nustendi - bempedoic acid / ezetimibe - EMEA/H/C/004959

FGK Representative Service GmbH; treatment of primary hypercholesterolaemia or mixed dyslipidaemia

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.11.2019. List of Questions adopted on 27.06.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that bempedoic acid is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 30.01.2020.

The summary of opinion was circulated for information.

3.1.10. Nubeqa - darolutamide - EMEA/H/C/004790

Bayer AG; treatment of non-metastatic castration resistant prostate cancer (nmCRPC)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.11.2019. List of Questions adopted on 25.07.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that darolutamide is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 29.01.2020.

The summary of opinion was circulated for information.

3.1.11. Ruxience - rituximab - EMEA/H/C/004696

Pfizer Europe MA EEIG; treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and Pemphigus vulgaris (PV)

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 13.12.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 30.01.2020.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.12. Rybelsus - semaglutide - EMEA/H/C/004953

Novo Nordisk A/S; treatment of type 2 diabetes mellitus

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 19.09.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 29.01.2020.

The summary of opinion was circulated for information.

3.1.13. Staquis - crisaborole - EMEA/H/C/004863

Pfizer Europe MA EEIG; treatment of mild to moderate atopic dermatitis

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 29.05.2019, 28.02.2019. List of Questions adopted on 20.09.2018.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that crisaborole is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 28.01.2020.

The summary of opinion was circulated for information.

3.1.14. Trepulmix - treprostinil sodium - Orphan - EMEA/H/C/005207

SciPharm Sarl; treatment of thromboembolic pulmonary hypertension (CTEPH)

Scope: Opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 27.06.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 29.01.2020.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.15. Vaxchora - cholera vaccine, oral, live - EMEA/H/C/003876

Emergent Netherlands B.V.; indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 6 years and older

Scope: Possible Oral explanation/Opinion

Action: Oral explanation to be held on Tuesday, 28 January 2020 at 14:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 17.10.2019. List of Questions adopted on 29.05.2019.

The CHMP agreed that no oral explanation is needed this time.

See 2.1

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that *V. cholerae* live attenuated strain CVD 103-HgR1 is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. indacaterol / mometasone furoate - EMEA/H/C/005067

treatment of asthma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 19.09.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. budesonide / glycopyrronium / formoterol fumarate dihydrate - EMEA/H/C/004983

as a maintenance treatment in adult patients with moderate to very severe chronic obstructive pulmonary disease (COPD)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 26.04.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

3.2.3. indacaterol / glycopyrronium / mometasone - EMEA/H/C/005061

treatment of asthma and to reduce asthma exacerbations

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 19.09.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. pretomanid - Orphan - EMEA/H/C/005167

FGK Representative Service GmbH; treatment of tuberculosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.07.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. selinexor - Orphan - EMEA/H/C/005127

Karyopharm Europe GmbH; treatment of patients with relapsed refractory multiple myeloma (RRMM)

Scope: Possible Oral explanation/List of Outstanding Issues

Action: Oral explanation to be held on Tuesday, 28 January 2020 at time 11:00

List of Outstanding Issues adopted on 19.09.2019. List of Questions adopted on 24.04.2019.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP agreed that no oral explanation is needed this time.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.6. indacaterol / glycopyrronium / mometasone - EMEA/H/C/005518

treatment of asthma and to reduce asthma exacerbations

Scope: List of outstanding issues

Action: For adoption

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. abiraterone acetate - EMEA/H/C/005408

treatment of metastatic prostate cancer

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. bevacizumab - EMEA/H/C/005181

treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer;
- first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer;
- first line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. bulevirtide - Orphan - EMEA/H/C/004854

Accelerated assessment

MYR GmbH; indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients with compensated liver disease.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. elexacaftor / tezacaftor / ivacaftor - Orphan - EMEA/H/C/005269

Vertex Pharmaceuticals (Ireland) Limited; treatment of cystic fibrosis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

Based on request of the applicant for a longer clock-stop, the CHMP agreed to revert to a standard timetable.

3.3.5. lenalidomide - EMEA/H/C/005306

treatment of multiple myeloma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. pegfilgrastim - EMEA/H/C/005085

treatment of neutropenia

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. somapacitan - Orphan - EMEA/H/C/005030

Novo Nordisk A/S; indicated for the replacement of endogenous GH with growth hormone deficiency (AGHD).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. abicipar pegol - EMEA/H/C/005103

treatment of neovascular (wet) age-related macular degeneration (AMD)

Scope: Letter from the applicant dated 24 January 2020 requesting an extension of clock-stop to respond to the list of questions adopted on 14.11.2019.

List of Questions adopted on 14.11.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted on 14.11.2019.

3.4.2. ioflupane (^{123}I) - EMEA/H/C/005135

is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum

Scope: Letter from the applicant dated 27 January 2020 requesting an extension of clock-stop to respond to the list of questions adopted on 14.11.2019.

List of Questions adopted on 14.11.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted on 14.11.2019.

3.4.3. satralizumab - Orphan - EMEA/H/C/004788

Roche Registration GmbH; treatment of adult and adolescent patients from 12 years of age with neuromyelitis optica spectrum disorders (NMOSD)

Scope: Letter from the applicant dated 23 January 2020 requesting an extension of clock-stop

Action: For adoption

List of Questions adopted on 12.12.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop.

3.4.4. rilpivirine - EMEA/H/C/005060

treatment of human immunodeficiency virus type 1 (HIV-1)

Scope: Letter from the applicant dated 24 January 2020 requesting an extension of clock-stop to respond to the list of questions adopted in December 2019.

Action: For adoption

List of Questions adopted on 12.12.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in December 2019.

3.4.5. entrectinib - EMEA/H/C/004936

treatment of adult and paediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive locally advanced or metastatic solid tumours and treatment of patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC).

Scope: Letter from the applicant dated 20 December 2019 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in December 2019.

Action: For adoption

List of Outstanding Issues adopted on 12.12.2019, 17.10.2019. List of Questions adopted

on 29.05.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues adopted in December 2019.

3.4.6. pexidartinib - Orphan - EMEA/H/C/004832

Daiichi Sankyo Europe GmbH; treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT), also referred to as giant cell tumour of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS)

Scope: Updated list of questions for SAG Oncology meeting

Action: For adoption

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 25.07.2019.

The CHMP adopted the updated list of questions for the SAG Oncology.

Call for additional experts for the SAG Oncology

3.4.7. cabotegravir - EMEA/H/C/004976

treatment of human immunodeficiency virus type 1 (HIV-1)

Scope: Letter from the applicant dated 24 January 2020 requesting an extension of clock-stop to respond to the list of questions adopted in December 2019.

Action: For adoption

List of Questions adopted on 12.12.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in December 2019.

3.4.8. ozanimod - EMEA/H/C/004835

Treatment of multiple sclerosis

Scope: Letter from the applicant dated 16 January 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in December 2019.

List of Questions to SAG Neurology

Action: For adoption

List of Outstanding Issues adopted on 12.12.2020. List of Questions adopted on 25.07.2019.

The CHMP adopted the list of questions to the SAG Neurology.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues adopted in December 2019.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Hopveus - sodium oxybate - EMEA/H/C/004962

D&A PHARMA; for the treatment of alcohol dependence

Scope: Draft list of experts to the ad-hoc expert group meeting

Letter from third party

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 17.10.2019. List of Outstanding Issues adopted on 26.04.2019. List of Questions adopted on 15.11.2018.

The CHMP noted the letter from a third party.

The CHMP adopted the draft list of experts for the ad-hoc expert group meeting as well as a list of questions to this group.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Halimatoz - adalimumab - EMEA/H/C/004866/X/0013

Sandoz GmbH

Rapporteur: Milena Stain, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to add a new strength of 20 mg (20 mg/0.4 ml) for Halimatoz solution for injection in pre-filled syringe.
The RMP (version 2.0) is updated in accordance. The MAH took also the opportunity to consolidate the RMP with changes approved in two other procedures (WS1565 and IB/11) and to align the PI with the latest QRD template (v.10.1)."

Action: For adoption

List of Questions adopted on 14.11.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.2. Hefiya - adalimumab - EMEA/H/C/004865/X/0013

Sandoz GmbH

Rapporteur: Milena Stain, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to add a new strength of 20 mg (20 mg/0.4 ml) for Hefiya solution for injection in pre-filled syringe.
The RMP (version 2.0) is updated in accordance. The MAH took also the opportunity to consolidate the RMP with changes approved in two other procedures (WS1565 and IB/10) and to align the PI with the latest QRD template (v.10.1)."

Action: For adoption

List of Questions adopted on 14.11.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.3. Hyrimoz - adalimumab - EMEA/H/C/004320/X/0013

Sandoz GmbH

Rapporteur: Milena Stain, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to add a new strength of 20 mg (20 mg/0.4 ml) for Hyrimoz solution for injection in pre-filled syringe.
The RMP (version 2.0) is updated in accordance. The MAH took also the opportunity to consolidate the RMP with changes approved in two other procedures (WS1565 and IB/11) and to align the PI with the latest QRD template (v.10.1)."

Action: For adoption

List of Questions adopted on 14.11.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

No items

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. IDELVION - albutrepenonacog alfa - Orphan - EMEA/H/C/003955/X/0035

CSL Behring GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add a new strength of 3500 IU (700 IU/ml) for albutrepenonacog alfa powder and solvent for solution for injection. The RMP version 3.1 was updated in accordance.
In addition, the applicant took the opportunity to update sections with editorial changes and align the dossier."

Action: For adoption

The Committee discussed the issues identified in this application, relating to some quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Pemetrexed Accord - pemetrexed - EMEA/H/C/004072/X/0010

Accord Healthcare S.L.U.

Rapporteur: John Joseph Borg, PRAC Rapporteur: Ghania Chamouni

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (25 mg/ml solution for infusion)"

Action: For adoption

The Committee discussed the issues identified in this application, relating to some quality aspects and SmPC updates.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.3. Velphoro - iron - EMEA/H/C/002705/X/0020/G

Vifor Fresenius Medical Care Renal Pharma France

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension application to add a new pharmaceutical form with a new strength -

powder for oral suspension 125 mg, and extension of indication to add indication to use Velphoro for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m^2) or with CKD on dialysis, based on the results from an open-label, randomised, active-controlled, parallel group, multicentre, phase 3 study investigating the safety and efficacy of Velphoro and calcium acetate in paediatric and adolescent CKD patients with hyperphosphataemia (Study PA-CL-PED-01). As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 7.0 has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to the indication wording in relation to the appropriate patient population and the request for a 1 year of market protection for a new indication.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0070

Takeda Pharma A/S

Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Treatment of adults with previously untreated CD30+ PTCL"

Action: For adoption

Request for Supplementary Information adopted on 17.10.2019.

The Committee discussed the issues identified in this application. Main issues discussed concerned the appropriate patient population as well as safety data in specific subgroups.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

The CHMP agreed to consult a SAG and adopted a list of question to this group.

5.1.2. Ameluz - 5-aminolevulinic acid - EMEA/H/C/002204/II/0039/G

Biofrontera Bioscience GmbH

Rapporteur: Janet Koenig, Co-Rapporteur: Peter Kiely

Scope: "C.I.6.a - To modify the approved therapeutic indication to include the treatment of mild to severe actinic keratosis on extremities, trunk and neck. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC and sections 1 and 4 of the PL are updated accordingly.
C.I.4 - To update section 5.1 of the SmPC based on follow-up data from study ALA-AK-CT009; this is a randomized, observer-blind, intra-individual phase III study to evaluate the safety and efficacy of Ameluz in combination with daylight PDT (photodynamic therapy) in comparison with Metvix for the treatment of mild to moderate actinic keratosis."

Action: For adoption

Request for Supplementary Information adopted on 12.12.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.3. CRYSVITA - burosumab - Orphan - EMEA/H/C/004275/II/0010/G

Kyowa Kirin Holdings B.V.

Rapporteur: Kristina Dunder, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adults with X-linked hypophosphataemia (XLH), and modification of the currently approved indication in children and adolescents, by removing the qualification 'with growing skeletons', in order to include treatment in all children with radiographic evidence of bone disease.
The application provides new week-48 data from Study UX023-CL304; a randomized, double-blind, placebo-controlled, phase 3 study with open-label extension to assess the efficacy and safety of KRN23 in adults with XLH. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated and the Package Leaflet is updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 10.1. The updated RMP version 2.0 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly concerning the clinical efficacy data.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.4. ECALTA - anidulafungin - EMEA/H/C/000788/II/0040

Pfizer Europe MA EEIG

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of the approved indication "treatment of invasive candidiasis (ICC)" to include paediatric patients aged from 1 month to less than 18 years of age; consequently, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated in order to add paediatric dosing instructions, warnings and precautions, clinical, and non-clinical information. The Package Leaflet is updated accordingly consequent to the revisions to the SmPC. In addition, the Marketing Authorisation Holder (MAH) has taken the opportunity to update the information in the SmPC and Package Leaflet in line with the current excipient's guideline for fructose.
The RMP Version number 13.0 dated 08 March 2019 which includes GVP module V rev 2 changes has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 19.09.2019.

The Committee discussed the issues identified in this application, concerning the wording in some SmPC sections.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.5. INTELENCE - etravirine - EMEA/H/C/000900/II/0058

Janssen-Cilag International NV

Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Adrien Inoubli

Scope: "To extend the approved therapeutic indication of Intelence in order to include patient population from 2 to 6 years of age based on the 48 week study results from study TMC125-C234/P1090 (A Phase I/II, Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and sections 1, 2 and 3 of the PL are updated accordingly. The updated RMP version 13.1 has also been submitted.
The RMP (version 13.1) of the product has been updated to remove the completed additional pharmacovigilance activities (TMC125-C234/P1090 (Week 48) and TMC125-EPPICC) from the pharmacovigilance plan of the RMP). The RMP has also been updated to meet the requirements and updated definitions in the European Medicines Agency (EMA) Guideline on good pharmacovigilance practices (GVP) Module V Revision 2 (EMA/838713/2011; Rev 2) and Guidance on the format of the RMP in the European Union (EMA/164014/2018 Rev 2.0.1) including proposed removal of safety concerns.

The MAH took the opportunity to include some typographic changes in Annex II C and D."

Action: For adoption

The Committee discussed the issues identified in this application, concerning some non-clinical and clinical aspects, in particular the posology and method of administration.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.6. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0082

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication to include new population for Kalydeco 150 mg tables to extend the use to patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have an R117H mutation in the CFTR gene and for Kalydeco granules 75 mg and 50 mg, to add patients with CF aged 12 months and older and weighing 7 kg to less than 25 kg who have an R117H mutation in the CFTR gene. This is based on a clinical trial and literature data, and post-marketing experience with Kalydeco. As a consequence, sections 4.1, 4.2, 4.4 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 8.5 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly in relation to the wording of the indication and the appropriate patient population.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.7. Kineret - anakinra - EMEA/H/C/000363/II/0070

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Mark Ainsworth, Co-Rapporteur: Fátima Ventura, PRAC Rapporteur: Hans Christian Siersted

Scope: "Extension of indication to include the treatment of Familial Mediterranean Fever (FMF) for Kineret, to be given in combination with colchicine, if appropriate; as a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 5.0 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly in relation to the wording of the indication and the appropriate patient population.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. Lynparza - olaparib - EMEA/H/C/003726/II/0033

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to support the use of Lynparza tablets (100 mg and 150 mg) for the maintenance treatment of gBRCAm metastatic pancreatic cancer based on the results from the pivotal Phase 3 study, POLO; as a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 4.8 for lynparza hard capsules (50 mg) to revise list of ADR based on the pooled safety data analysis. The RMP version 18 has also been submitted. Furthermore, the PI is brought in line with the latest guideline regarding the sodium content. The MAH also took the occasion to include some minor editorial changes in the PI."

Action: For adoption

Request for Supplementary Information adopted on 17.10.2019.

The Committee discussed the issues identified in this application, mainly relating to the clinical efficacy data supporting the extension of indication.

The Committee adopted a request for supplementary information with a specific timetable.

The CHMP agreed to consult the SAG Oncology and adopted a list of questions to this group.

Call for additional experts for the SAG Oncology.

5.1.9. MabThera - rituximab - EMEA/H/C/000165/II/0162

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Paula Boudewina van Hennik, PRAC
Rapporteur: Hans Christian Siersted

Scope: "Extension of indication to include the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active granulomatosis with polyangiitis (GPA) (Wegener's) and microscopic polyangiitis (MPA); as a consequence sections 1, 2, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.5, 8 of the SmPC are updated for MabThera 100 mg and 500 mg concentrate for solution for infusion. The PL was updated accordingly.
In addition, the product information for the MabThera 100 mg and 500 mg concentrate for solution for infusion have been combined. The RMP has been updated to version 21.1."

Action: For adoption

Request for Supplementary Information adopted on 12.12.2019, 17.10.2019, 29.05.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.10. MabThera - rituximab - EMEA/H/C/000165/II/0168

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Paula Boudewina van Hennik, PRAC

Rapporteur: Hans Christian Siersted

Scope: "Extension of indication in the treatment of paediatric patients (aged ⩾ 6 months to < 18 years old) with previously untreated advanced stage diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL) in combination with chemotherapy for MabThera; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
Changes to the annexes have been made based on the merging of the 100 mg and 500 mg MabThera IV strength information in SmPC sections 1, 2, 4.4 (excipients), 6.5 and 8 and in the PIL section header and section 6. Changes based on data from the paediatric study can be found in SmPC sections 4.1, 4.2, 4.4 (adding 'adult' identifier), 4.8, 5.1 and 5.2, and in the PIL sections 1, 2, 3, and 4. Minor corrections are also proposed for the sake of accuracy and clarity. An updated RMP (v21.1) is also included in this submission."

Action: For adoption

Request for Supplementary Information adopted on 19.09.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.11. Rezolsta - darunavir / cobicistat - EMEA/H/C/002819/II/0033

Janssen-Cilag International NV

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ilaria Baldelli

Scope: "To extend the approved therapeutic indication of Rezolsta to include the adolescent population (aged 12 years old and older with body weight at least 40 kg). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and sections 1, 2 and 3 of the PL are updated accordingly. The updated RMP version 6.0 has also been submitted. The RMP of the product has been updated to meet the requirements and updated definitions in the European Medicines Agency (EMA) Guideline on good pharmacovigilance practices (GVP) Module V Revision 2 (EMA/838713/2011; Rev 2) and Guidance on the format of the RMP in the European Union (EMA/164014/2018 Rev 2.0.1) including proposed removal of safety concerns.
In addition, in order to align the PI with recommendations for other HIV products, the MAH has also taken the opportunity to update section 4.2 of the SmPC and the product information with regards to the administration of Rezolsta in case of vomiting.
The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 17.10.2019.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.12. Ruconest - conestat alfa - EMEA/H/C/001223/II/0053/G

Pharming Group N.V

Rapporteur: Andrea Laslop, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Jan Neuhauser

Scope: "Update of indication to include children in the treatment of acute angioedema attacks with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. This is based from Study C1 1209 in children. In addition, final efficacy and safety data from the OLE phases of Studies C1 1304 and 1205 and the completed Study C1 1310 are submitted together with final study results of Studies C1 1207 and 3201, concerning prophylactic treatment of HAE patients. Consequently, the product information has been updated. Furthermore, the company is requesting an extension for the completion of registry Study C1 1412. The current RMP (V 18.0) states that completion of the final study report for Study C1 1412 is anticipated 31 March 2020. Although patient enrolment has increased, the study will not be completed on time. The MAH would therefore like to request an extension of the study completion date to submit the final report date for Study C1 1412 of 30 June 2022. In addition, as mentioned below, the RMP has also been aligned to RMP template version 2.0.1. The product information has also been updated to align with the most recent QRD template, version 10.1."

Action: For adoption

The Committee discussed the issues identified in this application, relating to some clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.13. Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/II/0011

sanofi-aventis groupe

Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include "treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors" based on the phase 3 Study EFC13794; a 26-week randomized, open-label, active controlled, parallel-group, study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin (alone or with pioglitazone and/or SGLT2 inhibitors), followed by a fixed ratio combination single-arm 26-week extension period.
As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to

update the contact details of the local representatives in Denmark, the Netherlands and Malta in the Package Leaflet and to implement minor editorial changes in the annexes. An updated RMP version 4.1 was agreed during the procedure."

Action: For adoption

Request for Supplementary Information adopted on 17.10.2019, 27.06.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.14. Taltz - ixekizumab - EMEA/H/C/003943/II/0031

Eli Lilly Nederland B.V.

Rapporteur: Kristina Dunder, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and adolescents who are candidates for systemic therapy for Taltz; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated with new safety and efficacy information. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 7.1 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly concerning the clinical efficacy and safety data in relation to body weight as well as potential medication errors.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.15. Tremfya - guselkumab - EMEA/H/C/004271/II/0017

Janssen-Cilag International N.V.

Rapporteur: Melinda Sobor, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Addition of a new indication for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. Consequently sections 4.1, 4.2 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package leaflet is updated accordingly. Additionally, minor QRD changes are introduced in annex II."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to the

clinical data for the different dosage regimes.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.16. Tybost - cobicistat - EMEA/H/C/002572/II/0051

Gilead Sciences Ireland UC

Rapporteur: Bruno Sepodes, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "To modify the approved therapeutic indication to include new population (adolescents aged 12 years and older, weighing at least 35 kg) for the treatment of HIV-1. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 of the SmPC and sections 1, 2, 3 of the PL are updated accordingly. The updated RMP version 5 is also been submitted"

Action: For adoption

Request for Supplementary Information adopted on 17.10.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.17. Venclyxto - venetoclax - EMEA/H/C/004106/II/0023/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Filip Josephson, PRAC Rapporteur: Eva Jirsová

Scope: "Extension of indication to include, in combination with an anti-CD20 antibody (obinutuzumab), treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) for Venclyxto based on the results of the pivotal CLL14/BO25323 phase 3 study; consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC and corresponding sections of the PL have been revised. The updated RMP version 5.4 has been agreed. Additionally, the SmPC section 5.3 has been updated based on the results of a 4-week dose ranging study, a 6-month carcinogenicity study and two embryo-foetal development (EFD) studies in mice. Minor editorial changes have been introduced throughout the Product Information.
The group of variations leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 17.10.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.18. WS1695
Braftovi - encorafenib - EMEA/H/C/004580/WS1695/0008
Mektovi - binimetinib - EMEA/H/C/004579/WS1695/0007

Pierre Fabre Medicament

Lead Rapporteur: Janet Koenig

Scope: "Extension of indication to include encorafenib in combination with binimetinib and cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy, as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 1.1 has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.1." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to the clinical data and subgroup analysis.

The Committee adopted a request for supplementary information with a specific timetable.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Brilique - ticagrelor - EMEA/H/C/001241/II/0047/G

AstraZeneca AB

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include, in co administration with acetylsalicylic acid (ASA), the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) without a history of myocardial infarction who have undergone percutaneous coronary intervention (PCI) based on the final results of study D513BC00001 (THEMIS), a phase III multinational, randomised, double-blind, placebo controlled study to evaluate the effect of ticagrelor twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with T2DM; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated.
Update of section 4.8 of the SmPC regarding with new safety information on traumatic haemorrhages based on the final results from study D513BC00001 (THEMIS) and data from the ticagrelor clinical development programme and post-marketing data.
The Package Leaflet is updated in accordance. The RMP version 12 has also been submitted."

Letter from the applicant dated 22 January 2020 requesting an extension of clock stop to

respond to the Request for Supplementary Information adopted on 14.11.2019.

Action: For adoption

Request for Supplementary Information adopted on 14.11.2019

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the Request for Supplementary Information adopted on 14.11.2019.

5.2.2. Fycompa - perampanel - EMEA/H/C/002434/II/0047

Eisai GmbH

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni

Scope: "Extension of indication to include adjunctive treatment in paediatric patients from 2 to 11 years of age in Partial-Onset (focal) Seizures with or without secondary generalisation and Primary Generalised Tonic-Clonic Seizures with idiopathic generalised epilepsy for Fycompa. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 4.3 has also been submitted." Clockstop extension requested to respond to RSI.

Action: For adoption

Request for Supplementary Information adopted on 12.12.2019.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the request for supplementary information adopted on 12.12.2019.

5.2.3. OFEV - nintedanib - Orphan - EMEA/H/C/003821/II/0026

Boehringer Ingelheim International GmbH

Rapporteur: Peter Kiely, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include new indication for OFEV for the treatment of Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. The MAH takes this opportunity to also introduce minor linguistic corrections to the Annexes for France and Sweden. The RMP version 7.0 has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Updated list of experts for the ad-hoc expert group meeting adopted via written procedure on 14 January 2020, Report from the ad-hoc expert group held on 22 January 2020 (see also OFEV II/27)

Action: For adoption

Request for Supplementary Information adopted on 14.11.2019, 27.06.2019.

The CHMP noted the report from the ad-hoc expert group meeting.

5.2.4. OFEV - nintedanib - Orphan - EMEA/H/C/003821/II/0027

Boehringer Ingelheim International GmbH

Rapporteur: Peter Kiely, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include new indication for OFEV for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype based on the results of pharmacology studies and the double-blind, randomised, placebo-controlled phase III trial (INBUILD). Consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to reflect the use of Ofev in the new indication. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor formatting changes in the PI. Furthermore, the PI is brought in line with the latest QRD template version 10.1. The RMP version 9.0 has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Updated list of experts for the ad-hoc expert group meeting adopted via written procedure on 14 January 2020, Report from the ad-hoc expert group held on 22 January 2020 (see also OFEV II/26)

Action: For adoption

Request for supplementary information adopted on 12.12.2019.

The CHMP noted the report from the ad-hoc expert group meeting.

5.2.5. Axumin - fluciclovine (^{18}F) - EMEA/H/C/004197/II/0011

Blue Earth Diagnostics Ireland Limited

Rapporteur: Janet Koenig, PRAC Rapporteur: Rugile Pilviniene

Scope: "Extension of indication to include Diagnosis and continuing assessment of Glioma in adult patients as a new indication for Axumin; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 5.1, 5.2 and 11 of the SmPC and the Annex II are updated. The Package Leaflet is updated in accordance." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Withdrawal of variation

Request for Supplementary Information adopted on 25.07.2019, 28.03.2019.

The CHMP noted the withdrawal of the variation application.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. crisantaspase - H0005424

treatment of patients with acute lymphoblastic leukaemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP **did not agree** to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.2. Combination of bifikafusp alfa and onfekafusp alfa - H0005385 and H0005370

intended for the treatment of stage IIIB and IIIC melanoma

Scope: Request for combination pack

Action: For adoption

The CHMP accepted the combination pack.

8.1.3. dostarlimab - H0005204

treatment of patients with recurrent or advanced mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) endometrial cancer (EC)

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP **agreed** to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Disclosure of information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 7 recommendations for eligibility to PRIME: 2 were granted and 5 were denied.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. ECALTA - anidulafungin - EMEA/H/C/000788

Pfizer Europe MA EEIG

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: DHPC and communication plan on market disruption adopted via written procedure on 10.01.2020

Action: For information

The CHMP noted the DHPC and communication plan which was adopted via written procedure on 10.01.2020.

9.1.2. Fexeric (EXP) - ferric citrate coordination complex - EMEA/H/C/003776

Akebia Europe Limited c/o Matheson

Rapporteur: Romaldas Mačiulaitis, Co-Rapporteur: Daniela Melchiorri

Scope: The marketing authorisation of Fexeric expired on 13 January 2020 due to end of the sunset clause

Action: For discussion

The CHMP noted the expiry of the marketing authorisation.

9.1.3. Olanzapine Apotex - olanzapine - EMEA/H/C/001178/II/0037

Apotex Europe BV; generic of Zyprexa

Rapporteur: John Joseph Borg

Scope: "Update of sections 4.8 and 4.4 in order to add information regarding the risk of metabolic syndrome with the use of olanzapine, based on review of the available data."

Action: For discussion

The Committee discussed the issues identified in this application, mainly relating to the wording of some sections of the SmPC of this product in relation to the SmPC of the originator product.

The Committee adopted a request for supplementary information with a specific timetable.

The CHMP agreed to consult the PRAC and adopted a list of question to this Committee.

9.1.4. Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/II/0049

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Update of section 4.8 of the SmPC with the safety data from the Phase 3, open-label, rollover study for Studies 109 and 011 Part B (Study 011B) designed to evaluate the long-term safety and tolerability of Orkambi treatment for 96 weeks in patients with cystic fibrosis, 6 years of age and older, homozygous for F508del."

Action: For discussion

Request for Supplementary Information adopted on 31.10.2019, 05.09.2019.

The Committee discussed the issues identified in this application, relating to the wording of some SmPC sections.

The CHMP adopted a 3rd a request for supplementary information with a specific timetable.

9.1.5. Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0049

Novartis Europharm Limited

Re-examination Rapporteur: Milena Stain and re-examination Co-Rapporteur: Sinan B Sarac

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include first line treatment of adult and paediatric patients aged 2 years and older with severe aplastic anaemia for Revolade in combination with IST; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 50 has also been updated."

Post-authorisation European Public Assessment Report

Action: For information

Opinion adopted on 17.10.2019, 27.06.2019. Oral explanation held on 24.06.2019. Request for Supplementary Information adopted on 28.02.2019, 15.11.2018, 26.07.2018.

The CHMP noted the Post-authorisation European Public Assessment Report.

9.1.6. Stelara - ustekinumab - EMEA/H/C/000958/II/0073

Janssen-Cilag International NV

Rapporteur: Jayne Crowe, Co-Rapporteur: Mark Ainsworth, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include the treatment of children aged 6 to 12 years with moderate to severe psoriasis for Stelara solution for injection; as a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Section 4.8 for Stelara concentrate for solution for infusion is updated accordingly. Minor editorial changes are made to section 4.5 for both formulations.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 16.1 has also been submitted."

Revised Opinion adopted via written procedure on 14 January 2020

Action: For information

The CHMP noted the revised opinion which was adopted via written procedure on 14.01.2020.

9.1.7. Varuby - rolapitant - EMEA/H/C/004196

Tesaro UK Limited; prevention of nausea and vomiting

Rapporteur: Alexandre Moreau, Co-Rapporteur: Peter Kiely

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

9.1.8. WS1587/G Abasaglar-EMEA/H/C/002835/WS1587/0028/G Humalog-EMEA/H/C/000088/WS1587/0178/G

Applicant: Eli Lilly Nederland B.V.

Lead rapporteur: Kristina Dunder

Scope: "Type II variation. B.IV.z. to introduce an additional prefilled pen presentation for Abasaglar, solution for injection (EU/1/14/944/007, EU/1/14/944/008, EU/1/14/944/012, EU/1/14/944/013), Humalog, solution for injection (EU/1/96/007/002, EU/1/96/007/004, EU/1/96/007/020, EU/1/96/007/021 EU/1/96/007/023), Humalog Kwikpen solution for injection (EU/1/96/007/031, EU/1/96/007/032, EU/1/96/007/039, EU/1/96/007/040, EU/1/96/007/041, EU/1/96/007/042) and Humalog Junior Kwikpen, solution for injection (EU/1/96/007/043, EU/1/96/007/044, EU/1/96/007/045). The pack contains 5 pre-filled pens.
Type IAIN B. II.e.5.a.1 to request the 2x5 multipack.
As a consequence, the following sections were updated 1, 4.2, 4.4, 6.2, 6.4, 6.5, 6.6, 8 of the SmPC in order to add new pre-filled pen presentation; the Package Leaflet and Labelling are updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to make an editorial change (removing comma in SK address in the PL)."

Letter from the applicant dated 07 January 2020 requesting an extension of clock-stop to respond to the request for supplementary information adopted on 14 November 2019 – adopted via written procedure on 17 January 2020.

Action: For information

Request for Supplementary Information adopted on 14.11.2019, 19.09.2019

The CHMP noted the updated timetable.

9.1.9. Yondelis - trabectedin- EMEA/H/C/000773

Pharma Mar, S.A.; treatment of soft tissue sarcoma and ovarian cancer

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jorge Camarero Jiménez

Scope: Risk assessment

Action: For discussion

The CHMP discussed the risk assessment.

9.1.10. Zynteglo - autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin BB305 lentiviral vector encoding the beta-A-T87Q-globin gene - EMEA/H/C/003691/R/0005, Orphan, ATMP

bluebird bio (Netherlands) B.V

CHMP Coordinator Rapporteur: Paula Boudewina van Hennik, CHMP Coordinator Co-Rapporteur: Alexander Moreau

Scope: Renewal

Action: For discussion

The CHMP was updated on discussions from the January 2020 CAT Plenary meeting.

The CHMP agreed to the request for supplementary information as adopted by the CAT.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Direct Oral Anticoagulants (DOAC) - EMEA/H/A-5(3)/1478

MAHs: various

Referral Rapporteur: Martina Weise, Referral Co-Rapporteurs: Kristina Dunder

Rapporteurs for involved CAPs:

Eliquis (APIXABAN):
Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Bart van der Schueren;

Pradaxa (DABIGATRAN ETEXILATE):
Rapporteur: Mark Ainsworth, Co-Rapporteur: Jean-Michel Race;

Xarelto (RIVAROXABAN):
Rapporteur: Kristina Dunder, Co-Rapporteur: Martina Weise

Scope: List of outstanding issues/Opinion

To assess the results of a non-interventional study regarding the risks of major bleeding in patients with non-valvular atrial fibrillation.

Action: For adoption

The CHMP discussed the results of a non-interventional study and agreed that the benefit/risk of the products remained unchanged. It was agreed that no regulatory actions were warranted.

10.2.2. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490

MAHs: various

Referral Rapporteur: Martina Weise, Referral Co-Rapporteurs: Kristina Dunder

Scope: Update on presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients

List of experts for the ad-hoc expert meeting scheduled on 27-28 February 2020

List of questions to the ad-hoc expert meeting scheduled on 27-28 February 2020 adopted via written procedure on 03 January 2020

List of questions to EU trade associations

Action: For adoption

The CHMP noted the feedback from the industry teleconference held on 27.01.2020.

The CHMP adopted a list of questions to the SWP.

The CHMP adopted a list of questions to industry.

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Budesonide SUN – budesonide – EMEA/H/A-29(4)/1492

Sun Pharmaceutical Industries Europe B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Giuseppa Pistritto

Scope: List of outstanding issues

Action: For adoption

The applicant has submitted an Art. 10(3) application for Budesonide SUN nebuliser suspension and associated names. Concerns regarding the demonstration of bioequivalence have been raised by IT and UK who were of the view that the data presented (comparative in vitro data of the product before nebulisation, including Particle Size Distribution (PSD) of the active substance) are not sufficient to demonstrate bioequivalence. The procedure was initiated because of disagreements regarding which in-vitro data are considered pivotal.

The CHMP adopted a list of questions to QWP.

The CHMP adopted list of outstanding issues with a specific timetable.

Submission of responses: 24.02.2020

Re-start of the procedure: 27.02.2020

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 10.03.2020

Comments: 16.03.2020

Updated Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 20.03.2020

CHMP opinion: March 2020 CHMP

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

January 2020 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the document.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections.

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections.

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections.

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 13-16 January 2020

Action: For information

The CHMP noted the Summary of recommendations and advice.

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for January 2020

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 22-24 January 2020

Action: For information

The CHMP noted the draft minutes.

14.2.3. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 13-15 January 2020

Action: For information

The CHMP noted the report.

14.2.4. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 20-22 January 2020

Action: For information

The CHMP noted the report.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP January 2020 meeting to CHMP for adoption:

- 12 reports on products in scientific advice and protocol assistance
- 7 reports on products in pre-authorisation procedures
- 1 report on products in post-authorisation procedures
- 4 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Central Nervous System Working Party (CNSWP)

Chair: Karl Broich/André Elferink

CMDh question to CNSWP- Bioequivalence requirements for Cmax for carbamazepine as NTI drug

Action: For adoption

The CHMP agreed to the CNS WP consultation.

14.3.3. Name Review Group (NRG)

Lipid complex formulations – safety concerns linked to naming

Action: For discussion

The CHMP agreed to the proposed addition of the 'lipid complex' qualifier to the concerned product.

14.3.4. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 13-16 January 2020. Table of conclusions

Action: For information

Scientific advice letters:

Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.5. Safety Working Party (SWP)

CMDh list of questions to SWP on mutagenic impurity from promazine

The CHMP endorsed the SWP consultation.

14.3.6. Quality Working Party (QWP)

CMDh consultation of QWP on QP declaration

The CHMP endorsed the QWP consultation.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

14.7.1. CHMP 2020 Work Plan

Action: For adoption

The CHMP adopted the work plan 2020.

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Presentation on Corona Viruses

Action: For information

The CHMP was updated on the current situation.

15.1.2. Oncology Training

Action: For information

The oncology training was postponed.

16. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/ experts following evaluation of declared interests for the January 2020 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Milena Stain	Alternate	Austria	No interests declared	
Christophe Focke	Alternate	Belgium	No restrictions applicable to this meeting	
Mila Vlaskovska	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Loizos Panayi	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czech Republic	No interests declared	
Tomas Radimersky	Alternate - remote participation	Czech Republic	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Mark Ainsworth	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Melinda Sobor	Member	Hungary	No restrictions applicable to this meeting	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Daniela Melchiorri	Member	Italy	No restrictions applicable to this meeting	
Giuseppa Pistritto	Alternate	Italy	No interests declared	
Natalja Karpova	Member	Latvia	No interests declared	
Simona Stankeviciute	Alternate	Lithuania	No interests declared	
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions applicable to this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Marcin Kolakowski	Alternate	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No restrictions applicable to this meeting	
Simona Badoi	Member	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Rajko Kenda	Member	Slovenia	No restrictions applicable to this meeting	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Jorge Camarero Jiménez	Alternate	Spain	No participation in final	MabThera - rituximab - EMEA/H/C/000165/II/0162 MabThera - rituximab -

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
			deliberations and voting on:	EMEA/H/C/000165/II/0168
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Nithyanandan Nagercoil	Member	United Kingdom	No restrictions applicable to this meeting	
Christian Gartner	Co-opted member	Austria	No restrictions applicable to this meeting	
Koenraad Norga	Co-opted member	Belgium	No participation in final deliberations and voting on:	dostarlimab - H0005204 Varuby - rolapitant - EMEA/H/C/004196
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czech Republic	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Kirstine Moll Harboe	Expert - in person*	Denmark	No interests declared	
Mette Tranholm	Expert - in person*	Denmark	No interests declared	
Sabine Mayrhofer	Expert - in person*	Germany	No interests declared	
Alida Spruijt	Expert - in person*	Netherlands	No interests declared	
Berendina Maria van den Hoorn	Expert - in person*	Netherlands	No interests declared	
Helene Blok	Expert - in person*	Netherlands	No interests declared	
Ingrid Evers van Gogh	Expert - in person*	Netherlands	No interests declared	
Jaap Goedemoed	Expert - in person*	Netherlands	No interests declared	
Johannes Petrus Theodorus Span	Expert - in person*	Netherlands	No interests declared	
Joost Romme	Expert - in person*	Netherlands	No interests declared	
Monique van Raamsdonk	Expert - in person*	Netherlands	No interests declared	
Sabine Straus	Expert - in person*	Netherlands	No interests declared	
Anja Schiel	Expert - in person*	Norway	No interests declared	
Erlend Johannessen Egeland	Expert - in person*	Norway	No interests declared	
Andreas Bronden	Expert - via telephone*	Denmark	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Doris Hovgaard	Expert - via telephone*	Denmark	No interests declared	
Johanna Lahteenvuo	Expert - via telephone*	Finland	No interests declared	
Karri Penttila	Expert - via telephone*	Finland	No interests declared	
Kimmo Jaakkola	Expert - via telephone*	Finland	No interests declared	
Olli Tenhunen	Expert - via telephone*	Finland	No interests declared	
Nathalie Morgensztejn	Expert - via telephone*	France	No interests declared	
Serge Bakchine	Expert - via telephone*	France	No interests declared	
Marion Haberkamp	Expert - via telephone*	Germany	No interests declared	
Jeanette McCallion	Expert - via telephone*	Ireland	No interests declared	
Rosemary Maher	Expert - via telephone*	Ireland	No restrictions applicable to this meeting	
Cristina Migali	Expert - via telephone*	Italy	No interests declared	
Babs Fabriek	Expert - via telephone*	Netherlands	No interests declared	
Helene Blok	Expert - via telephone*	Netherlands	No interests declared	
Hinke Johanna van der Woude	Expert - via telephone*	Netherlands	No interests declared	
Miki Hew	Expert - via telephone*	Netherlands	No interests declared	
Monique van Raamsdonk	Expert - via telephone*	Netherlands	No interests declared	
Nienke Rodenhuis	Expert - via telephone*	Netherlands	No interests declared	
Peter Mol	Expert - via telephone*	Netherlands	No interests declared	
Ine Skottheim Rusten	Expert - via telephone*	Norway	No interests declared	
Maria Almlof	Expert - via telephone*	Norway	No interests declared	
Therese Solstad	Expert - via telephone*	Norway	No interests declared	
Venke Skibeli	Expert - via telephone*	Norway	No interests declared	
Candida Silva	Expert - via telephone*	Portugal	No interests declared	
Ernesto Vera	Expert - via telephone*	Spain	No interests declared	
Lauri Soinne	Expert - via telephone*	Sweden	Direct interests declared	
Maria Luttgen	Expert - via telephone*	Sweden	Indirect interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Olga Kholmanskikh	Expert - via Adobe*	Belgium	No interests declared	
Adriana Andric	Expert - via Adobe*	Croatia	No interests declared	
Juha Kolehmainen	Expert - via Adobe*	Finland	No interests declared	
Clemens Mittmann	Expert - via Adobe*	Germany	No interests declared	
Adriana Ammassari	Expert - via Adobe*	Italy	No interests declared	
Valentina Conti	Expert - via Adobe*	Italy	No interests declared	
Andre Elferink	Expert - via Adobe*	Netherlands	No interests declared	
Aina Jannicke Ovrebust	Expert - via Adobe*	Norway	No interests declared	
Meeting run with the help of EMA staff				

*Experts were only evaluated against the product(s) they have been invited to talk about.

17. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/